Pharmacoeconomic review report. Teriflunomide (Aubagio — Genzyme Canada) indication: relapsing-remitting multiple sclerosis
CADTH
Record ID 32015000170
English
Authors' recommendations:
CDR found several limitations with the manufacturer's economic analysis. A reanalysis addressing all of these limitations (except treatment waning over time) found that teriflunomide dominated Rebif and Avonex, but the ICUR for teriflunomide versus GA was $409,175.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/cdr/pharmacoeconomic/SR0350_Aubagio_PE_Report_e.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Multiple Sclerosis, Relapsing-Remitting
- Immunosuppressive Agents
- Anti-Inflammatory Agents, Non-Steroidal
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.